Irene Garcia-Fogeda¹, Hajar Besbassi¹, Ynke Larivière^{2,3}, Benson Ogunjimi^{4,5,6}, Steven Abrams^{2,7}, Niel Hens^{1,7}

¹ Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine Infectious Diseases Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium ² Global Health Institute (GHI), Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium

³ Centre for the Evaluation of Vaccination, Vaccine Infectious Diseases Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium


⁴ Antwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), Antwerp, Belgium

⁵ Antwerp Center for Translational Immunology and Virology (ACTIV), Vaccine Infectious Diseases Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium ⁶ Department of Paediatrics, University Hospital Antwerp, Antwerp, Belgium

⁷ Data Science Institute (DSI), Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BioStat), UHasselt, Hasselt, Belgium

Background

Understanding the mechanisms of within-host kinetics of the humoral (and cellular) immune response to a viral, parasite, or bacterial infection is crucial to foresee better intervention strategies in the context of infectious Figure 1: Flow describing the diseases.



dynamics of uninfected cells, infected cells, and infectious virus

Objectives





Fig. 2: Classification of the within-host mathematical models

To identify within-host mechanistic modeling approaches to study humoral immunity processes after vaccination or natural infection. This is crucial to unravel the specific components of the immune system and their dynamics.


Methodology

The search strategy of our **systematic review** and eligibility criteria are summarized as follows:



Results

To date, only 20 publications out of 77 have relied on mechanistic models to study the dynamics of humoral immunity.



* Refers to which studies have used Bayesian approaches

Contact information








How have Bayesian methods been applied in the parameter estimation of such models?

Vaccine-induced setting: Berbers et al., [5]

Estimation of the model parameters and prediction of the peak antibody concentrations together with halfantibody values were performed using Hierarchical Bayesian methods and Monte Carlo Markov Chain (MCMC).

- Simple exponential decay
- Parametric distributions for the antibody growth and decay (e.g., Gamma, Inverse gamma).



Natural infection setting: White et al., [2]

White et al., [2] studied the impact of maternal immunity on Malaria infections in children.

MCMC iteration using a random walk Metropolis-Hastings algorithm (Model 1):

1. Local parameter (n)

- $\vec{\theta^{n'}} = [d_m^{n'}, d_a^{n'}, A_m^n, \theta_1^n ... \theta_N^n]$
- $L_{mix}^{n}(\theta_{n}'|D_{n})$
- Accept probability $min = \left\{1, \frac{L_{mix}^n(\theta_n'|D_n)}{L_{mix}^n(\theta_n|D_n)}\right\}$
- 2. Nuisance parameter (n)
 - $\vec{\theta^{n'}} = [d_m^n, d_a^n, A_m^{n'}, \theta_1^{n'}...\theta_N^{n'}]$
 - $L_{mix}^n(\theta_n'|D_n)$
 - Accept probability $min = \left\{1, \frac{L_{mix}^n(\theta_n'|D_n)}{L_{mix}^n(\theta_n|D_n)}\right\}$
- 3. Global parameter
 - $\vec{\theta} = [d'_m, d'_a, \sigma'_m, \sigma'_a, \sigma'_{obs}, \theta^1 ... \theta^N]$
 - Calculate the total likelihood $L_{TOTAL}(\theta'|D_n)$ and update the prior $P(\theta')$
 - Accept probability $min = \left\{1, \frac{L_{TOTAL}(\theta'|D) * P(\theta')}{L_{TOTAL}(\theta|D) * P(\theta)}\right\}$

Truncated normally distributed measurement error 200 million MCMC iterations computed with acceptance rates using Robins-Munro algorithm.

Natural infection setting: Teunis et al., [6]

Teunis et al, [6] extended the work by de Graaf et al., [7] defining multiple antibody production sites defined as c_k below.

Infection and waning immunity process respectively

$$b'(t) = \mu_0 * b(t) - \sum c_k * y_k(t)$$

$$y'_k(t) = \mu_k * y_k(t)$$

$$b(t) = 0$$

$$y'_k(t) = -w_k^* * y_k(t)$$

What functions are studied? {Bi-exponential decay

Non-exponential decay Power functions

All models used 3 chains and 10^6 iterations. A multivariate normal prior was chosen for the different model parameters, and a Wishart distribution for the random effects.

References

- [1] Garcia-Fogeda, I., Besbassi, H., Larivière, Y., Ogunjimi, B., Abrams, S., and Hens, N. (2023). Within-host modeling to measure dynamics of antibody responses after natural infection or vaccination: A systematic review.
- [2] White, M. T., Griffin, J. T., Akpogheneta, O., Conway, D. J., Koram, K. A., Riley, E. M., Ghani, A. C. (2014). Dynamics of the antibody response to Plasmodium falciparum infection in African children. The Journal of infectious diseases, 210(7), 1115–1122. https://doi.org/10.1093/infdis/jiu219
- [3] Gelman, A., Hwang, J., and Vehtari, A. (2013). Understanding predictive information criteria for Bayesian models. Statistics and Computing [4] Handel, A., Brown, J., Stallknecht, D., Rohani, P. (2013). A multi-scale analysis of influenza A virus fitness trade-offs due to temperature-dependent virus persistence. PLoS computational biology, 9(3), e1002989. https://doi.org/10.1371/journal.pcbi.1002989
- [5] Berbers, G. A., van de Wetering, M. S., van Gageldonk, P. G., Schellekens, J. F., Versteegh, F. G., and Teunis, P. F. (2013). A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens. Vaccine, 31(36), 3732–3738. https://doi.org/10.1016/j.vaccine.2013.05.073
- [6] Teunis, P. F., van Eijkeren, J. C., de Graaf, W. F., Marinovi´c, A. B., Kretzschmar, M. E. (2016). Linking the seroresponse to infection to within-host heterogeneity in antibody production. Epidemics, 16, 33–39. https://doi.org/10.1016/j.epidem.2016.04.001
- [7] de Graaf, W. F., Kretzschmar, M. E., Teunis, P. F., and Diekmann, O. (2014). A two-phase within-host model for immune response and its application to serological profiles of pertussis. Epidemics, 9, 1–7.

Findings

1. COMPARTMENTS

- Data-driven approaches: Typically study the interaction between pathogen growth with antibody production, or the dynamics between short- and long-living cells with antibodies.
- Theory-driven approaches: Typically study more complicated processes, starting from susceptible cells population to neutralizing antibody production.

2. PARAMETERS

- Data-driven approaches: Linear, nonlinear mixed approaches. Exponential decay, bi-exponential, power functions. Smoothing functions and binary functions represent normally the time of vaccination.
- Theory-driven approaches: Simulation approaches to generate the parameters (e.g., Poisson or Binomial distributions).

3. INFERENCE/ANALYTICAL ANALYSES

- Data-driven approaches: Use of Maximum likelihood estimation (MLE) and Bayesian hierarchical approaches with Monte Carlo Markov Chain (MCMC).
- Theory-driven approaches: Model's equilibria and stability.

4. COVARIATES

Study groups are widely studied. However, there is a lack of information on geographical background, surveillance systems, and age.

5. MODEL COMPARISON

- Data-driven approaches: Difficulties in Bayesian approaches due to the number of parameters and complexity of the models. WAIC (Watanabe-Akaike information criteria) for future modelling work. AIC (Akaike information criteria) within MLE [3].
- Theory-driven approaches: Comparison to simulated data.

6. SOFTWARE IN BAYESIAN METHODS

• Monolix, JAGS.

Conclusion

• More research is needed on the **methods of in**ference in data-driven mechanistic models, such as semi-parametric to full parametric tools.

- Biological mechanisms must be distinguished in vaccination or natural infection settings.
- There is not a lot of software that can perform ODEs with Bayesian hierarchical approaches.

Acknowledgments

IGF and NH acknowledge support from the EBOVAC3 project which has received funding from the IMI2 Joint Undertaking under grant agreement No 800176 (IMI-EU). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme, European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Coalition for Epidemic Preparedness Innovations (CEPI).







